Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$106.83 USD

106.83
243,843

+0.31 (0.29%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $106.89 +0.06 (0.06%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BrainsWay (BWAY) Expands Foothold in Taiwan With Deep TMS

by Zacks Equity Research

The collaboration between BrainsWay (BWAY) and Unison Healthcare Group signifies a coordinated effort to enhance access and awareness of Deep TMS in Taiwan.

Zacks Equity Research

LabCorp (LH) Suffers From Lower COVID Test Sales, Macro Woes

by Zacks Equity Research

Labcorp's (LH) Early Development Research Laboratories business continues to be constrained by NHP-related supply-chain issues.

Zacks Equity Research

Charles River (CRL) Collaborates With Fondazione Telethon

by Zacks Equity Research

Charles River (CRL) is excited about Fondazione Telethon's collaboration to produce HQ plasmid DNA for the lentivirus used in ex vivo gene therapy developed by Fondazione Telethon.

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) on the expanded global installed base of more than 3,250 Panthers instruments, representing the catalyst for sustained growth.

Zacks Equity Research

Veeva Systems (VEEV) to Support Civica Rx Quality Control

by Zacks Equity Research

Veeva Systems' (VEEV) Vault LIMS will streamline internal testing and manufacturing while promoting lead time adherence.

Zacks Equity Research

Thermo Fisher (TMO) Launches New Chromosomal Microarray

by Zacks Equity Research

Thermo Fisher's (TMO) CytoScan HD Accel array can save labs weeks or even months by accelerating the time it takes to get findings from cytogenetic research.

Zacks Equity Research

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Up (Revised)

by Zacks Equity Research

Strength across businesses and geographies, driven by execution, innovation, and improved underlying fundamentals contributes to Medtronic (MDT) Q1 revenues.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) successful integration of the recently-acquired business and raised guidance.

Zacks Equity Research

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Strength across businesses and geographies, driven by execution, innovation and improved underlying fundamentals, contributes to Medtronic's (MDT) Q1 revenues.

Zacks Equity Research

Here's Why You Should Invest in Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN), led by Invisalign portfolio expansion and raised guidance.

Zacks Equity Research

3 Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Zacks Equity Research

Here's Why You Should Invest in Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are upbeat about Penumbra (PEN) on Strong uptake following the launch of Lightning Flash, which accelerated top-line growth.

Zacks Equity Research

What's in the Cards for Medtronic (MDT) in Q1 Earnings?

by Zacks Equity Research

Strength across all businesses is likely to drive Medtronic's (MDT) first-quarter performance.

Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

The Zacks Analyst Blog Highlights Abcam, Integer Holdings and RxSight

by Zacks Equity Research

Abcam, Integer Holdings and RxSight are part of the Zacks top Analyst Blog.

Zacks Equity Research

TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant

by Zacks Equity Research

TransMedics' (TMDX) acquisition of Summit Aviation is likely to help establish TransMedics Aviation, the first integrated national provider of air logistics dedicated exclusively to organ transplantation.

Zacks Equity Research

Phibro's (PAHC) Sales Hurt by Rising Costs, FX Headwind

by Zacks Equity Research

Phibro (PAHC) input costs continue to be high as a result of sustained inflation.

Zacks Equity Research

Neogen (NEOG) Introduces New Genomic Data Management Tool

by Zacks Equity Research

Neogen's (NEOG) new Igenity Enhanced Dairy offers farmers valid data and assesses their herd's potential. It helps them make the most informed decisions.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health's (CVS) continued growth across the insured and self-insured medical, pharmacy, dental and behavioral health products and services.

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Potential to Fight Deflation Risk

by Indrajit Bandyopadhyay

Here we discuss three medical devices stocks, ABCM, ITGR and RXST, which have robust growth outlook in the long term. Betting on these stocks will help investors offset any potential deflationary risk.

Zacks Equity Research

Thermo Fisher (TMO) Completes the CorEvitas Acquisition

by Zacks Equity Research

Thermo Fisher's (TMO) latest buyout is likely to deliver $0.03 in adjusted earnings per share in 2024 and be marginally accretive in 2023.

Zacks Equity Research

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on its strategic expansion in the global market and recovery within the Nutrition segment.

Zacks Equity Research

Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement

by Zacks Equity Research

Myriad Genetics' (MYGN) GeneSight report will contain details on how a patient's smoking history may affect their metabolism of certain medications.

Zacks Equity Research

Here's Why You Should Invest in Alcon (ALC) Stock Now

by Zacks Equity Research

Investors are optimistic about Alcon (ALC) owing to its strength in Surgical and Vision Care franchises and upbeat 2023 guidance.

Zacks Equity Research

Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

by Zacks Equity Research

Illumina (ILMN) shipped 109 NovaSeq X instruments in the second quarter, boosting its supply capacity to more than 390 instruments for fiscal 2023.